In Massachusetts, Lilly Asia Ventures, Trustbridge Partners, and Jiangsu Simcere Pharmaceutical gave Veritas Genetics $30 million in Series B funding. Veritas Genetics focuses on genome sequencing and genetic screening tests, mostly related to cancer and reproductive health. Veritas was the first company to offer genetic sequencing for under $1,000, making it a realistic prospect for more people. Mirza Cifric, founder and CEO of Veritas Genetics, told PR Newswire, “With a $999 genome, we are at the tipping point of a transformation in healthcare where the genome is going to be at the center of many decisions we make about our health and quality of life, throughout our lives.” This latest funding will go towards global expansion of operations and hospital and researcher partnerships. They welcomed three new executives to their team to help with the expansion, Tim Smith as Chief Operating Officer, Rodrigo Martinez as Chief Marketing and Design Officer, and Doug Flood as Chief Commercial Officer.
Latest article
Meatable hosts distinguished guests for EU’s first cultivated meat tasting
In the Netherlands, Meatable has hosted the European Union’s first cultivated meat tasting. Michelin-starred chef Ron Blaauw; Constantijn van Oranje, Prince of the Netherlands...
Cool as a cucumber (coating): Sweden’s Saveggy raises $2.1 million for edible produce preserver
In Sweden, foodtech startup Saveggy has raised €1.76 (US$2.1 million) to scale up an edible cucumber coating made from a proprietary formula of canola...
Designer develops chitin-based seed pods
In New York, designer Mara Zimmerman has developed SEAD, a seed delivery and cultivation material made from discarded seafood cells.
Specifically, Zimmerman uses chitin from...